


# Author's Accepted Manuscript

Inhibition of alpha oscillations through serotonin 2A receptor activation underlies the visual effects of ayahuasca in humans

Marta Valle, Ana Elda Maqueda, Mireia Rabella, Aina Rodríguez-Pujadas, Rosa Maria Antonijoan, Sergio Romero, Joan Francesc Alonso, Miquel Àngel Mañanas, Steven Barker, Pablo Friedlander Msc, Amanda Feilding, Jordi Riba



PII: S0924-977X(16)30010-4  
DOI: <http://dx.doi.org/10.1016/j.euroneuro.2016.03.012>  
Reference: NEUPSY11240

To appear in: *European Neuropsychopharmacology*

Received date: 2 August 2015  
Revised date: 2 March 2016  
Accepted date: 19 March 2016

Cite this article as: Marta Valle, Ana Elda Maqueda, Mireia Rabella, Aina Rodríguez-Pujadas, Rosa Maria Antonijoan, Sergio Romero, Joan Francesc Alonso, Miquel Àngel Mañanas, Steven Barker, Pablo Friedlander Msc, Amanda Feilding and Jordi Riba, Inhibition of alpha oscillations through serotonin 2A receptor activation underlies the visual effects of ayahuasca in humans, *European Neuropsychopharmacology*, <http://dx.doi.org/10.1016/j.euroneuro.2016.03.012>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

# Inhibition of alpha oscillations through serotonin 2A receptor

## activation underlies the visual effects of ayahuasca in humans

Ketanserin and ayahuasca

Marta Valle PhD<sup>1,2,3,4</sup>, Ana Elda Maqueda MSc<sup>3,5</sup>, Mireia Rabella MSc<sup>3,6</sup>, Aina Rodríguez-Pujadas PhD<sup>5</sup>, Rosa Maria Antonijoan PhD<sup>2,3,4</sup>, Sergio Romero PhD<sup>7,8</sup>, Joan Francesc Alonso PhD<sup>7,8,9</sup>, Miquel Àngel Mañanas PhD<sup>7,8,9</sup>, Steven Barker PhD<sup>10</sup>, Pablo Friedlander Msc<sup>11</sup>, Amanda Feilding MSc<sup>11</sup>, Jordi Riba PhD<sup>2,3,4,5</sup>

<sup>1</sup> Pharmacokinetic and Pharmacodynamic Modelling and Simulation, IIB Sant Pau. Sant Antoni Maria Claret, 167, 08025 Barcelona, Spain.

<sup>2</sup> Centre d'Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau. Sant Antoni Maria Claret, 167, 08025, Barcelona, Spain.

<sup>3</sup> Department of Pharmacology and Therapeutics, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.

<sup>4</sup> Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain.

<sup>5</sup> Human Neuropsychopharmacology Group. Sant Pau Institute of Biomedical Research (IIB-Sant Pau). Sant Antoni Maria Claret, 167. 08025, Barcelona, Spain.

<sup>6</sup> Servei de Psiquiatria, Hospital de la Santa Creu i Sant Pau. Sant Antoni Maria Claret, 167. 08025, Barcelona, Spain.

<sup>7</sup> Biomedical Engineering Research Centre (CREB), Department of Automatic Control (ESAI), Universitat Politècnica de Catalunya (UPC), Barcelona, Spain.

<sup>8</sup> CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Spain.

<sup>9</sup> Barcelona College of Industrial Engineering (EUETIB), Universitat Politècnica de Catalunya (UPC), Barcelona 08028, Spain.

<sup>10</sup> Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, LA 70803, USA.

<sup>11</sup> The Beckley Foundation, Beckley Park, Oxford OX3 9SY, United Kingdom

**Correspondence to:** Jordi Riba. Human Neuropsychopharmacology Group, IIB-Sant Pau. Sant Antoni Maria Claret, 167.08025, Barcelona, Spain. Phone: +34 93 556 5518. Fax: +34 93 553 7855. Email: jriba@santpau.cat

Ayahuasca is an Amazonian psychotropic plant tea typically obtained from two plants, *Banisteriopsis caapi* and *Psychotria viridis*. It contains the psychedelic 5-HT<sub>2A</sub> and sigma-1 agonist *N,N*-dimethyltryptamine (DMT) plus  $\beta$ -carboline alkaloids with monoamine-oxidase (MAO)-inhibiting properties. Although the psychoactive effects of ayahuasca have commonly been attributed solely to agonism at the 5-HT<sub>2A</sub> receptor, the molecular target of classical psychedelics, this has not been tested experimentally. Here we wished to study the contribution of the 5-HT<sub>2A</sub> receptor to the neurophysiological and psychological effects of ayahuasca in humans. We measured drug-induced changes in spontaneous brain oscillations and subjective effects in a double-blind randomized placebo-controlled study involving the oral administration of ayahuasca (0.75 mg DMT/kg body weight) and the 5-HT<sub>2A</sub> antagonist ketanserin (40 mg). Twelve healthy, experienced psychedelic users (5 females) participated in four experimental sessions in which they received the following drug combinations: placebo+placebo, placebo+ayahuasca, ketanserin+placebo and ketanserin+ayahuasca. Ayahuasca induced EEG power decreases in the delta, theta and alpha frequency bands. Current density in alpha-band oscillations in parietal and occipital cortex was inversely correlated with the intensity of visual imagery induced by ayahuasca. Pretreatment with ketanserin inhibited neurophysiological modifications, reduced the correlation between alpha and visual effects, and attenuated the intensity of the subjective experience. These findings suggest that despite the chemical complexity of ayahuasca, 5-HT<sub>2A</sub> activation plays a key role in the neurophysiological and visual effects of ayahuasca in humans.

**Key words:** Ayahuasca, serotonin-<sub>2A</sub> receptor, ketanserin, subjective effects, neurophysiological effects, human

Ayahuasca is a psychoactive plant tea used traditionally by the indigenous peoples of the Upper Amazon (Schultes, 1980) and in more recent times by healers and members of religious syncretic groups (Tupper, 2008). This tea is receiving increased attention from the general public and biomedical researchers (Frood, 2015). It has been used to help treat addiction (Fernández et al., 2014), and recent open-label studies have shown preliminary evidence of rapid and lasting antidepressant effects after a single dose (Osório et al., 2015; Sanches et al., 2015).

Although there are many variations in the preparation of the tea, the common ingredient is the malpighiaceae vine *Banisteriopsis caapi*. This plant is rich in  $\beta$ -carboline alkaloids, mainly harmine, harmaline and tetrahydroharmine (THH) (Riba, 2003). These alkaloids show monoamine-oxidase inhibiting properties (N S Buckholtz and Boggan, 1977), while THH is also a serotonin reuptake inhibitor (N. S. Buckholtz and Boggan, 1977). In addition to *B. caapi*, other admixture plants are frequently used in the preparation of ayahuasca. One of the most common in the context of modern use is *Psychotria viridis*. The leaves of this plant are rich in the psychedelic indole *N,N*-dimethyltryptamine or DMT (Riba, 2003).

DMT is structurally related to the neurotransmitter serotonin (5-hydroxytryptamine; 5-HT) and shows agonist activity at the 5-HT<sub>2A</sub> and 5-HT<sub>1A</sub> receptors. DMT also acts as an agonist at the trace amine associated receptor (TAAR) (Bunzow et al., 2001) and it is a substrate of the serotonin and the vesicle monoamine transporters (Cozzi et al., 2009). It has been suggested that using these uptake mechanisms, intracellular concentrations could reach higher values than in plasma and interact with the intracellular sigma-1 receptor (Fontanilla et al., 2009). This receptor modulates the activity of many other proteins, conferring stability against cellular stress, and promoting brain plasticity (Chu and Ruoho, 2016; Tsai et al., 2009).

ACCEPTED MANUSCRIPT

When administered to humans parenterally, DMT induces intense modifications of the ordinary state of awareness with intense visual effects, but it is devoid of psychoactivity when taken orally (Riba et al., 2015) due to degradation by MAO (Suzuki et al., 1981), and cytochrome-dependent mechanisms (Riba et al., 2015). The presence of the MAO-inhibiting  $\beta$ -carbolines in ayahuasca prevents its enzymatic degradation and allows its oral bioavailability (Riba et al., 2003a).

In previous studies by our group, we found ayahuasca to induce a pattern of psychedelic effects with a slower onset and longer duration than those induced by DMT (Dos Santos et al., 2011; Riba et al., 2003a, 2001b). Neurophysiologically, ayahuasca induces broad-band power decreases in spontaneous electrical brain oscillations (Riba et al., 2002a) and associated reductions in intracerebral current source density (CSD) in certain brain areas (Riba et al., 2004). These reductions are particularly strong for oscillations in the alpha band of the EEG, with CSD reductions over the posterior visual cortex, an effect thought to reflect increased cortical excitability (Romei et al., 2008b). Analogous findings in the range of the alpha band have also been observed using magnetoencephalography and the psychedelic and serotonin- $2_A$  receptor agonist psilocybin (Muthukumaraswamy et al., 2013).

The aim of this study was to assess the contribution of serotonin- $2_A$  receptor to the neurophysiological and psychological effects of ayahuasca. We postulated that despite the combination of various pharmacological mechanisms in ayahuasca, the general psychedelic effects and decreases in current density depend on activation of the 5-HT $_{2A}$  receptor. To test this hypothesis, we studied the interaction of a medium dose of ayahuasca (Riba et al., 2001b) and ketanserin, a 5-HT $_{2A}$  receptor antagonist, in a group of experienced psychedelic users in a laboratory setting.

## Participants

For ethical reasons, we only recruited individuals with prior experience with psychedelics. We wanted to avoid introducing drug-naive individuals to psychedelics, and to make sure that volunteers would be familiar with the modified state of consciousness induced by these drugs. We therefore contacted psychedelic drug users and informed them about the goals of the study, the nature of ayahuasca, its psychological effects, and the potential adverse effects described in the literature for psychedelics. We recruited a group of 12 healthy volunteers (5 females, 7 males) with previous experience with psychedelic drugs (10 times or more). Despite their experience with psychoactive substances, no participant had a current or previous DSM/ICD-10 diagnosis of drug dependence.

The volunteers had a mean age of 35 years (26-43). Their past experience with psychedelic drugs mainly involved LSD (11/12), Psilocybe mushrooms (11/12) and ayahuasca (8/12). Nine of the participants also had experience with ketamine, six had used 2C-B, five had smoked *Salvia divinorum*, four had taken mescaline-containing cacti such as *peyote* or *San Pedro*, and two had smoked dimethyltryptamine. At the time of the study, eight were using cannabis sporadically (1-2 cigarettes per week). Only four were currently tobacco smokers and eleven consumed alcohol in moderate amounts, from one or two beers or glasses of wine per day to one per month.

Prior to participation, all volunteers underwent a complete medical examination that included medical history, physical examination, ECG, and standard laboratory tests, to confirm good health. Exclusion criteria included a current or past history of psychiatric disorders, alcohol or other substance use disorders, evidence of significant illness, and pregnancy. The study was conducted in accordance with the Declaration of Helsinki and subsequent amendments concerning research in humans and was approved

ACCEPTED MANUSCRIPT  
by the Sant Pau Hospital Ethics Committee and the Spanish Ministry of Health. All volunteers gave their written informed consent to participate.

## **Drugs**

Ayahuasca was administered in freeze-dried encapsulated form. The ayahuasca batch used in the study was analyzed using a previously described method using liquid chromatography-electrospray ionization-tandem mass spectrometry (McIlhenny et al., 2009). The analysis showed that ayahuasca contained the following alkaloid concentrations in mg per gram of freeze-dried material: 6.51 DMT, 13.14 harmine, 1.35 harmaline and 11.55 THH. The final dose was calculated individually for each participant, so that they received the equivalent of 0.75 mg DMT/kg body weight. The dose chosen is of medium intensity and was selected based on data from previous studies where it showed robust psychological and physiological effects (Dos Santos et al., 2012; Riba et al., 2001b). Given the alkaloid proportions present in the freeze-dried material, at the 0.75 mg/kg DMT dose, participants also ingested 1.51 mg/kg of harmine, 0.16 mg/kg of harmaline and 1.33 mg/kg of THH.

Ketanserin was administered as the trademark drug Ketensin (ketanserin tartrate), at the dose of 40 mg, and placebo capsules contained lactose.

## **Study design and drug administration**

The study was conducted according to a double-blind, randomized, balanced, crossover design. It involved four experimental sessions one week apart each. Two weeks prior to the first experimental session and throughout the study, participants abstained from any psychoactive drugs and medications. Urine was collected for drug analysis on each experimental day. Participants tested negative for alcohol, cannabis, amphetamines, benzodiazepines, opiates and cocaine. In each session, participants

ACCEPTED MANUSCRIPT

received an initial treatment that could be placebo (lactose capsule) or 40 mg ketanserin. One hour later, they were administered a second placebo or encapsulated freeze-dried ayahuasca. Thus, on each experimental day, participants received one of four different treatment combinations: placebo+placebo, placebo+ayahuasca, ketanserin+placebo and ketanserin+ayahuasca.

Participants remained in the laboratory for 8 hours after which they were discharged home. During the first four hours they remained seated in a reclining chair in a sound-attenuated and dimly lit room. EEG recordings were conducted before the administration of the first treatment (placebo or ketanserin). Ninety minutes after administration of the second treatment (ayahuasca or placebo), when the peak ayahuasca effects were expected, a second EEG recording was obtained. Four hours after administration of the second treatment, when most of the subjective effects of ayahuasca had disappeared, the volunteers were allowed to leave the room and were asked to answer the subjective effects questionnaires.

## **Data collection**

### *EEG recording and processing*

Three-minute EEG recordings with eyes closed were obtained from 19 standard scalp locations (Fp1/2, F3/4, Fz, F7/8, C3/4, Cz, T3/4, T5/6, P3/4, Pz and O1/2). Recordings were obtained using a BrainAmp amplifier (Brain Products GmbH, Gilching, Germany) before the first treatment (baseline) and 90 minutes after administration of the second treatment. Signals were referenced to the averaged mastoid electrodes, and vertical and horizontal electrooculograms (EOG) were also obtained for artifact minimization and removal. Signals were analogically band-pass filtered between 0.1 and 45 Hz, digitized with a frequency of 250 Hz.



EEG artifact minimization and removal was performed according to a two-step procedure before calculating the parameters. First, an ocular artifact minimization step was implemented using a previously described method based on blind source separation or BSS (Alonso et al., 2010; Romero et al., 2008). The continuous EEG recording was then segmented into 5 second epochs. These segments were automatically analyzed for saturation, muscular and movement artifacts using the procedure described by Anderer and colleagues (Anderer et al., 1992).

After computing the two-step artifact preprocessing procedure, spectral analysis was performed for all EEG channels. Power spectral density (PSD) functions were calculated from artifact-free 5 second epochs by means of a periodogram using a Hanning window, and averaged. Averaged PSD functions for each experimental situation were quantified into absolute powers in the following frequency bands: delta (0.5–3.5 Hz), theta (3.5–7.5 Hz), alpha (7.5-13 Hz), and beta (13-35 Hz). Additionally, frequency variability was measured calculating the deviation of the center-of-gravity frequency or centroid of the total activity (0.5-35 Hz).

#### *Intracerebral current density calculation*

The Standardized LORETA (sLORETA) software (Pascual-Marqui et al., 1994) was used to estimate the three-dimensional intracerebral current density distribution from the voltage values recorded at the scalp. sLORETA estimates a particular solution of the non-unique EEG inverse solution restricted to 6239 cortical grey matter voxels with a spatial resolution of  $0.125 \text{ cm}^3$  according to a digitized head model from Montreal Neurological Institute (Pascual-Marqui, 2002). The current density values were estimated based on the EEG cross-spectral matrix and then squared for each voxel in the classical frequency bands.

The psychological effects elicited by the administered treatments were measured using a battery of questionnaires on subjective effects: the Hallucinogen Rating Scale (HRS), the Addiction Research Center Inventory (ARCI), the Altered States of Consciousness Questionnaire (APZ), and a battery of self-administered visual analogue scales (VAS).

The Hallucinogen Rating Scale (HRS), developed by Strassman and colleagues (Strassman et al., 1994), includes 71 items grouped in six subscales: *Somaesthesia*, reflecting somatic effects; *Affect*, measuring emotional and affective responses; *Perception*, measuring visual, auditory, gustatory, and olfactory experiences; *Cognition*, describing modifications in thought processes or content; *Volition*, indicating the volunteer's capacity to willfully interact with his/her "self" and/or the environment; and *Intensity*, which reflects the strength of the overall experience. The range of scores for all scales is 0-4. A validated Spanish version was administered (Riba et al., 2001a).

The Addiction Research Center Inventory (ARCI) (Martin et al., 1971) includes 49 items distributed in five scales or groups: the morphine-benzedrine group (MBG) that measures euphoria; the pentobarbital-chlorpromazine-alcohol group (PCAG), that measures sedation; the lysergic acid diethylamide scale (LSD), that measures somatic-dysphoric effects; the benzedrine group (BG) that measures subjectively experienced intellectual efficiency; and the amphetamine scale (A), which is sensitive to stimulants. The range of scores is 0-16 for MBG, -4 to 11 for PCAG, -4 to 10 for LSD, -4 to 9 for BG, and 0-11 for A. A validated Spanish version was administered (Lamas et al., 1994).

The Altered States of Consciousness questionnaire ("Aussergewöhnliche Psychische Zustände", APZ) (Dittrich, 1998) is composed of 72 items distributed in three subscales: Oceanic Boundlessness ("Ozeanische Selbst-entgrenzung", OSE), to measure changes in the sense of time, derealization and depersonalization; Dread of

Ego-Dissolution (“Angstvolle IchAuflösung”, AIA), for measuring thought disorder and decreased body and thought control associated with arousal and anxiety; and Visionary Restructuralization (“Visionäre Umstrukturierung”, VUS), referring to visual phenomena such as illusions, hallucinations and synesthesia and to changes in the significance of objects. The range of scores is 0-13 for OSE, 0-22 for AIA, and 0-14 for VUS. We administered a Spanish version of the questionnaire that had been used previously in clinical studies involving psychedelic drugs (Riba et al., 2002b).

A battery of self-administered visual analogue scales (VAS) was used to retrospectively rate peak effects during the session. Volunteers indicated the intensity of the drug effects on a grid of (from 0=no effects to 100=extremely intense effects) 100-mm horizontal lines. There were ten VAS lines labeled as follows: “Any effect” indicated any effect, either physical or psychological, that the volunteer attributed to the administered dosage; “Good effects” indicated any effect the volunteer assessed as good; “Bad effects” indicated any effect the volunteer assessed as bad; “Liking” indicated that the volunteer liked the effects of the administered substance; “Fear” indicated apprehension or psychological discomfort; “Time” indicated modifications on the perception of time; “Feeling high” indicated any psychological alteration the participant attributed to the administered drug; “Changes in external reality” indicated changes in perception of external reality; “Loss of contact with external reality” indicated separation from the surroundings; and “Visions” indicated visual modifications with eyes open or closed.

As mentioned above, despite their recreational drug use, participants had no current or past diagnosis of substance use disorders. Consequently, we did not study the effects on ayahuasca on specific measures of addiction.

*EEG data*

Statistical analysis of EEG recordings was performed following the IPEG (International Pharmacology-EEG Group) guidelines for statistical design and analysis of pharmacodynamic trials (Ferber et al., 1999). Paired t-tests were carried out for all variables and EEG electrodes for assessing drug-induced changes at the 90 minute time point. Statistical results were displayed as topographic significance probability maps.

*Intracerebral current density data*

Statistical differences between treatments and placebo were evaluated by paired-sample t-tests computed for the baseline-corrected and log-transformed LORETA power values in each voxel and for each frequency band at the 90 minute time point. To correct for multiple comparisons, a non-parametric permutations test (NPT) based on the theory of randomization was applied (Nichols and Holmes, 2002). Voxel intensity NPT calculates a critical t-value by means of a random sample of all the possible permutations to estimate the distribution of the maximum t-statistic.

*Subjective effect measures*

Scores on the HRS, ARCI, APZ, and ARCI questionnaires were analyzed using repeated-measures ANOVAs with treatment as factor (placebo+placebo, placebo+ayahuasca, ketanserin+placebo, ketanserin+ayahuasca). When significant effects were found in the ANOVA, post-hoc pair-wise comparisons between treatments were conducted using Student's t-tests followed by Bonferroni correction. Results were considered significant for p values <0.05.

## Neurophysiological effects

### *Topography*

Figure 1 shows the topographical scalp maps of drug-induced changes in power in the different frequency bands following the three active treatments vs. placebo. Ayahuasca induced widespread absolute power decreases in the delta, theta and alpha frequency bands but did not induce any effects in absolute power the beta frequency range. Desynchronization of the EEG was evidenced by the reduction in the alpha rhythm and the increase in frequency variability indicated by the deviation of the center-of-gravity frequency. Ketanserin on its own showed effects opposed to those of ayahuasca. It increased absolute power in the delta band at the frontal leads and induced more widespread increases in the theta band. No effects were observed in the topographical scalp maps in the alpha and beta bands and only marginal decreases were seen in the centroid deviation. The administration of ketanserin prior to ayahuasca not only counteracted the delta and theta decreases but led to more marked and widespread increases in power throughout the scalp in these two frequency bands than those elicited by ketanserin alone. Ketanserin completely blocked the alpha decreases induced by ayahuasca and reverted the effects on the deviation of the center-of-gravity frequency.

-----  
Insert Figure 1 about here  
-----

### *Intracerebral current density data*

Figure 2 shows the intracerebral analysis of the topographical changes and Table 1 shows the associated data. The most intense effects observed for ayahuasca were current density decreases in the alpha band in posterior brain regions involving the

occipital, parietal, and temporal lobes. The highest decrease was located in the primary visual cortex in Brodmann area (BA) 18. Smaller significant areas were found in the frontal lobe. Theta decreases mainly involved the lateral and medial aspects of the frontal lobes. The highest decrease was located in the superior frontal gyrus in BA 10. Decreases in the delta band were found in the temporal lobe, with the highest decrease in the inferior temporal gyrus in BA 20.

-----  
Insert Figure 2 about here  
-----

Ketanserin on its own did not induce any changes in current source density in the alpha and delta bands. However, it induced increases in theta in the frontal lobe, specifically in the middle frontal gyrus in BA 6.

The administration of ketanserin as pretreatment abolished the alpha decreases induced by ayahuasca. Ketanserin also reverted the decreases in theta and led to increases in power in this band over extensive areas (see Table 1). The highest increases were observed in the frontal lobe, over the precentral gyrus in BA 44. Finally, ketanserin inhibited the delta decreases and led to increases in the occipital lobe and, to a lower extent, in the parietal lobe. The highest increase was observed in the cuneus in BA 30.

### *Subjective effects*

#### HRS

Figure 3 shows mean scores on the six subscales of the HRS after the four different treatments and Table 2 shows the results of the statistical analyses. Ayahuasca

significantly increased scores on all subscales except Volition. Ketanserin on its own did not induce any significant changes relative to placebo. When ayahuasca was preceded by ketanserin (ketanserin+ayahuasca combination), the 5-HT<sub>2A</sub> antagonist significantly reduced scores on Affect (62% reduction), Perception (56% reduction) and Intensity (36% reduction) subscales. An interesting deviant effect was observed in the Volition subscale. The ketanserin+ayahuasca combination yielded scores that were significantly higher than those after placebo. As shown in the figure, the combination had an additive effect, increasing incapacitation further than ayahuasca or ketanserin alone (76% increase relative to ayahuasca alone). Ketanserin reduced the scores on the somatic and cognitive effects induced by ayahuasca, but these reductions did not reach statistical significance.

-----  
Insert Figure 3 about here  
-----

## ARCI

Figure 3 shows the mean scores on the five subscales of the ARCI, and Table 2 shows the results of the statistical analyses. Ayahuasca significantly increased scores on the MBG, LSD and A subscales. As observed for HRS, ketanserin on its own did not induce any significant changes on any subscale.

When ketanserin preceded ayahuasca, the effects on the MBG subscale were significantly blocked (80% reduction), and no statistically significant differences were found between the combination and placebo. Analogously, ketanserin significantly reduced scores on the A subscale (53% reduction). Again, results after ketanserin+ayahuasca did not differ from placebo. Scores on the LSD subscale were not

ACCEPTED MANUSCRIPT  
blocked by ketanserin. Scores after the combination were significantly higher than those after placebo and were not significantly different from those after ayahuasca alone.

Ketanserin not only blocked but reversed the effects of ayahuasca on BG, with values falling clearly below those after placebo. This effect of a reduction in subjectively perceived intellectual efficiency is consistent with the effects induced by the ketanserin+ayahuasca combination on the PCAG scale. Scores on this sedation scale were not modified by ayahuasca alone but were markedly increased after the combination ( $\approx 20$  times higher). As shown in the figure, mean values after ketanserin+ayahuasca were higher than the mere addition of the effects induced by ayahuasca plus those after ketanserin.

In summary, ketanserin effectively blocked the euphoriant (MBG) and stimulant effects of ayahuasca (BG, A) but not its somato-dysphoric effects (LSD). Furthermore, it caused marked sedative effects when combined with ayahuasca (PCAG).

## APZ

Mean scores on all subscales of the APZ are shown in Figure 3, and the results of the statistical analyses in Table 2.

Ayahuasca significantly increased scores on all three subscales, whereas ketanserin alone did not induce any effects. Scores after ketanserin+ayahuasca were significantly lower than those after ayahuasca alone. However, values in the VUS subscale measuring visual phenomena were still different from placebo. Thus, although ayahuasca effects on the APZ were not completely abolished by ketanserin, they were markedly reduced by this drug: 65% reduction for OSE, 55% for AIA and 44% for VUS.



Mean scores on all VAS items are shown in Figure 4, and the results of the statistical analyses are shown in Table 3.

Ayahuasca significantly increased scores on all items except “bad effects”, “fear” and “loss of contact with external reality”. Again, ketanserin alone did not induce changes in any item. Scores after ketanserin+ayahuasca were significantly lower than after ayahuasca alone in the “any effect” (38%), “good effects” (62%), “liking” (61%), “time” (13%), “feeling high” (55%), “changes in external reality” (59%), and “visions” (38%). However, scores on “any effect”, “time”, “feeling high”, and “visions” were still significantly higher than after placebo. Thus, results on the VAS also suggest ketanserin partially blocked the subjective effects induced by ayahuasca.

-----  
Insert Figure 4 about here  
-----

### Correlation analysis

A correlation analysis was conducted between the ayahuasca-induced current density and subjective effects changes. Decreases in alpha correlated with the intensity of “visual effects” ( $r=-0.593$ ,  $p=0.042$ ) and showed a trend toward significance with the APZ-VUS subscale ( $r=-0.512$ ,  $p=0.059$ ). These correlations were reduced and significance was lost in the ketanserin+ayahuasca combination: VAS “visual effects” ( $r=-0.412$ ,  $p=0.183$ ) and APZ-VUS ( $r=-0.321$ ,  $p=0.310$ ). Decreases in theta correlated with changes in VAS “contact with external reality” ( $r=-0.591$ ,  $p=0.043$ ). Again, correlation values were reduced and significance was lost after the ketanserin

pretreatment ( $r=-0.384$ ,  $p=0.217$ ). Decreases in delta also correlated with changes in contact with external reality ( $r=-0.724$ ,  $p=0.008$ ). This correlation was also reduced and significance was lost in the ketanserin+ayahuasca combination ( $r=-0.179$ ,  $p=0.578$ ). Scatter plots for several statistically significant correlations are shown in Figure 5.

-----  
Insert Figure 5 about here  
-----

Accepted manuscript

The present study assessed the contribution of 5-HT<sub>2A</sub> receptors to the neurophysiological and subjective effects of ayahuasca in humans. Results showed that at the administered dose ayahuasca induced significant psychedelic effects and power decreases in the delta-alpha frequency range. Decreases in alpha-band oscillations had their source in posterior brain regions and correlated with the intensity of the visual modifications induced by ayahuasca. Ketanserin effectively blocked these decreases and reduced this correlation, suggesting a prominent role of the 5-HT<sub>2A</sub> receptor in the neurophysiological and visionary effects of ayahuasca.

The pattern of subjective effects is also in agreement with prior studies with ayahuasca. The 0.75 mg DMT/kg body weight ayahuasca dose chosen for the present experiment was an intermediate dose used in prior experiments by our group (Dos Santos et al., 2012; Riba et al., 2001b). It effectively induced a transient modified state of awareness characterized by introspection, increased affect and visual phenomena with eyes closed.

The broadband power reductions observed in oscillatory activity replicate results in the literature and are consistent with the previous study by our group involving ayahuasca at the dose of 0.85 mg/kg body weight and scalp topography analysis (Riba et al., 2002a). Our results concerning the source location analysis also agree with a previous study in which broad-band power reductions were localized to parieto-temporo-occipital regions and to a lesser extent to the medial prefrontal/anterior cingulate cortex (Riba et al., 2004). This pattern of neurophysiological effects has been demonstrated for other psychedelics. Komater and colleagues, also using EEG, have found that psilocybin-induces reductions in spontaneous alpha oscillations (Komater et al., 2013). Muthukumaraswamy and coworkers using magnetoencephalography, a technique that measures the magnetic component of brain oscillations, have also

ACCEPTED MANUSCRIPT  
described that psilocybin decreases power of the magnetic signal in a wide range of frequencies, from delta to high gamma (Muthukumaraswamy et al., 2013).

Energy decreases in brain oscillations suggest an excitatory effect of ayahuasca and psychedelics on the cortex. Studies in animals show that psychedelics induce excitatory postsynaptic potentials and currents (Kłodzinska et al., 2002). Further, the spontaneous alpha rhythm exerts an inhibitory role on the visual cortex in the occipital and parietal lobes (Romei et al., 2010, 2008a). Decreases in alpha rhythm are coupled with increased regional metabolism (Moosmann et al., 2003). This inverse relationship between EEG alpha power and increased cortical activity has also been seen in PET studies of blood flow (Buchsbaum et al., 1984), and more recently in studies using fMRI. A negative correlation has been found between alpha and BOLD in the anterior cingulate and in the parieto-occipital cortex (de Munck et al., 2007; Goldman et al., 2002; Laufs et al., 2003), a negative relationship that has been extended to the theta and beta bands of the EEG (de Munck et al., 2009).

Our results support an excitatory effect of ayahuasca on cortical regions involved in the processing of visual sensory information (alpha-occipital), memory-affect (delta-medial temporal lobe or MTL), and cognition-affect (theta-frontolateral and frontomedial cortex). Suppression of inhibitory alpha in the visual network, an area rich in 5-HT<sub>2A</sub> receptors (Savli et al., 2012), potentially led to the visionary phenomena experienced by participants in the absence of external cues (eyes closed). Analogous to our current findings, Kometer and colleagues found that ketanserin blocked psilocybin-induced reductions in alpha oscillations (Kometer et al., 2013). The marked attenuation of alpha decrease and the reduction of visual effects obtained for the ketanserin+ayahuasca pretreatment suggests that both effects are mediated by 5-HT<sub>2A</sub> receptor activation.

ACCEPTED MANUSCRIPT

Increased sensory excitability in posterior visual areas fits the findings of a recent study assessing ayahuasca effects on directed functional connectivity (Alonso et al., 2015) well. Using Transfer Entropy and Granger Causality, the authors found that, under ayahuasca, oscillations in posterior regions increased their influence over signals measured at anterior locations. Conversely, oscillatory activity at frontal sources decreased its influence over activity at occipital sites. The authors interpreted their findings in terms of increased feed-forward or bottom-up information transfer and decreased feed-back or top-down control. Our findings would support 5-HT<sub>2A</sub> agonism as a key mechanism in the modification of brain dynamics induced by ayahuasca (McKenna and Riba, 2015).

Ayahuasca administration in the present study led to significant increases in measures of affective modifications, in agreement with previous results (Dos Santos et al., 2011; Riba et al., 2006, 2003b). We also found EEG power reductions in areas associated with affective processing, i.e., the MTL and the medial frontal lobe/anterior cingulate cortex (ACC). Power decreases and increased blood flow in these regions had been reported previously using LORETA (Riba et al., 2004) and SPECT (Riba et al., 2006), respectively. The amygdala in the MTL and the ACC are key hubs of affective processing. The amygdala is associated with fear and emotional arousal, whereas the ACC and neighboring medial frontal areas integrate emotion and cognition. Effects at these levels have been proposed to underlie the therapeutic potential of ayahuasca (Soler et al., 2015). Ketanserin led to a 62% reduction in the HRS-Affect, subscale, an 80% reduction in the ARCI-MBG (positive mood/euphoria), and antagonized the delta and theta decreases in these regions. These results indicate a prominent role of 5-HT<sub>2A</sub> activation in the affective effects of ayahuasca and warrant future studies of the cognitive aspects of emotional processing during the ayahuasca experience.

ACCEPTED MANUSCRIPT

An unexpected finding was that while ketanserin decreased the overall intensity of the subjective experience, blockade was only partial. This finding contrasts with more intense inhibition found in studies involving psilocybin. Vollenweider and colleagues, for example, administered the same ketanserin dose (40 mg) prior to a high oral dose of 25 mg psilocybin and obtained reductions between 75% and 98% in the intensity of visual effects (Vollenweider et al., 1998). Examining the individual data in our study we found that two participants had a deviant pattern in their scores, with higher scores (60 and 100 mm, respectively) on the VAS-Visions item after the ketanserin+ayahuasca combination than after ayahuasca alone (14 and 74 mm, respectively). If these two participants are removed from the sample, the global mean for this item rises to 60 mm after ayahuasca and drops to 27 mm after the combination. However, even if we removed these two outliers, the inhibition of visual effects in our study would still be far from the suppression levels attained by Vollenweider.

One possible explanation for these unexpected results is that DMT interacts with other receptors in addition to 5-HT<sub>2A</sub>. Indolealkylamines such as DMT and psilocybin also show agonist effects at the 5-HT<sub>1A</sub> sites. These predominantly pre-synaptic receptors are present in large amounts in the raphe nuclei and their activation suppresses serotonin release. They are also present in the visual cortex, but they exert an inhibitory effect (Gerstl et al., 2008; Moreau et al., 2010). It is therefore doubtful that increased 5-HT<sub>1A</sub> activation by DMT in the presence of ketanserin increases visual phenomena. However, 5-HT<sub>1A</sub> agonism may have been responsible for the marked sedation experienced by participants when given the combination (indicated for instance by the high score on the ARCI-PCAG subscale obtained for the combination). Reductions in vigilance and attentional performance have been observed for the combination of ketanserin plus psilocybin (Carter et al., 2005). Theta power increases, as seen in our

ACCEPTED MANUSCRIPT  
experiment for ayahuasca+ketanserin, are the characteristic effects of the anxiolytic - HT<sub>1A</sub> agonist buspirone (Barbanoj, MJ et al., 1994).

DMT shows additional mechanistic differences from other psychedelics, which might account for the partial blockade of the observed effects. For instance, in contrast to the prototypical 5-HT<sub>2A</sub> agonist 2,5-dimethoxy-4-iodoamphetamine (DOI), DMT induces a weak behavioral head twitch response in animals (Carbonaro et al., 2015) and unlike LSD, it does not seem to lead to acute tolerance (Dos Santos et al., 2012; Strassman et al., 1996). Molecular mechanisms specific to DMT are agonism at the trace amine associated receptor (TAAR) (Bunzow et al., 2001); the fact that DMT is a substrate of both the serotonin and the vesicle monoamine transporters (Cozzi et al., 2009); and that it modulates the intracellular sigma-1 receptor (Fontanilla et al., 2009).

The sigma-1 receptor is a chaperone protein localized in the endoplasmic reticulum. It is involved in the regulation of many other proteins and signaling pathways and it has a protective role in cell survival (Chu and Ruoho, 2016; Hayashi and Su, 2007). It is also involved in neural plasticity, as it promotes dendritic spine and synapse formation (Tsai et al., 2009). Abnormal function of the sigma-1 receptor has been associated with various neurodegenerative disorders (Tsai et al., 2014). It is noteworthy that several antidepressants, such as fluvoxamine and sertraline show high affinity for this receptor (Rousseaux and Greene, 2015). It can be speculated that sigma-1 activation by DMT could play a role mediating the antidepressant effects found for ayahuasca (Osório et al., 2015; Sanches et al., 2015). These mechanisms should be addressed in future studies.

As a limitation of the study we would like to mention that volunteer recruitment emphasized previous experience with psychedelic drugs. Although participants had no present or previous diagnosis of drug dependence, detailed information on the dose, frequency and duration of consumption of other drugs was not collected.

To sum up, the present study assessed the contribution of the 5-HT<sub>2A</sub> receptor to the neurophysiological and psychological effects of ayahuasca. Ayahuasca induced an intense inhibitory effect on alpha oscillations in the parieto-occipito-temporal cortex that correlated with visual phenomena, a hallmark of the ayahuasca experience. The selective 5-HT<sub>2A</sub> receptor antagonist ketanserin effectively inhibited neurophysiological modifications, reduced the correlation between alpha and the visual effects, and attenuated the intensity of the subjective experience. These findings suggest that despite the chemical complexity of ayahuasca, 5-HT<sub>2A</sub> activation may especially contribute to its visual perceptual effects. Future studies should assess the role of other molecular mechanisms, such as sigma-1 agonism, in the perceptual, affective and cognitive effects of DMT and ayahuasca.

Accepted manuscript



- Alonso, J.F., Mañanas, M.A., Romero, S., Hoyer, D., Riba, J., Barbanoj, M.J., 2010. Drug effect on EEG connectivity assessed by linear and nonlinear couplings. *Hum. Brain Mapp.* 31, 487–497.
- Alonso, J.F., Romero, S., Mañanas, M.À., Riba, J., 2015. Serotonergic psychedelics temporarily modify information transfer in humans. *Int. J. Neuropsychopharmacol.* pii: pyv039
- Anderer, P., Semlitsch, H.V., Saletu, B., Barbanoj, M.J., 1992. Artifact processing in topographic mapping of electroencephalographic activity in neuropsychopharmacology. *Psychiatry Res.* 45, 79–93.
- Barbanoj, MJ, Anderer, P, Antonijuan, R, Torrent, J, Saletu, B, Jané, F, 1994. Topographic pharmaco-EEG mapping of increasing doses of buspirone and its comparison with diazepam. *Hum. Psychopharmacol. Clin. Exp.* 9, 101–109.
- Buchsbaum, M.S., Kessler, R., King, A., Johnson, J., Cappelletti, J., 1984. Simultaneous cerebral glucography with positron emission tomography and topographic electroencephalography. *Prog. Brain Res.* 62, 263–269.
- Buckholtz, N.S., Boggan, W.O., 1977. Monoamine oxidase inhibition in brain and liver produced by beta-carbolines: structure-activity relationships and substrate specificity. *Biochem. Pharmacol.* 26, 1991–1996.
- Buckholtz, N.S., Boggan, W.O., 1977. Inhibition by beta-carbolines of monoamine uptake into a synaptosomal preparation: structure-activity relationships. *Life Sci.* 20, 2093–2099.
- Bunzow, J.R., Sonders, M.S., Arttamangkul, S., Harrison, L.M., Zhang, G., Quigley, D.I., Darland, T., Suchland, K.L., Pasumamula, S., Kennedy, J.L., Olson, S.B., Magenis, R.E., Amara, S.G., Grandy, D.K., 2001. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites

Mol. Pharmacol. 60, 1181–1188.

- Carbonaro, T.M., Eshleman, A.J., Forster, M.J., Cheng, K., Rice, K.C., Gatch, M.B., 2015. The role of 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub> and mGlu<sub>2</sub> receptors in the behavioral effects of tryptamine hallucinogens N,N-dimethyltryptamine and N,N-diisopropyltryptamine in rats and mice. *Psychopharmacology (Berl.)* 232, 275–284.
- Carter, O.L., Burr, D.C., Pettigrew, J.D., Wallis, G.M., Hasler, F., Vollenweider, F.X., 2005. Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. *J. Cogn. Neurosci.* 17, 1497–1508.
- Chu, U.B., Ruoho, A.E., 2016. Biochemical Pharmacology of the Sigma-1 Receptor. *Mol. Pharmacol.* 89, 142–153.
- Cozzi, N.V., Gopalakrishnan, A., Anderson, L.L., Feih, J.T., Shulgin, A.T., Daley, P.F., Ruoho, A.E., 2009. Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter. *J. Neural Transm. Vienna Austria* 1996 116, 1591–1599.
- de Munck, J.C., Gonçalves, S.I., Huijboom, L., Kuijer, J.P.A., Pouwels, P.J.W., Heethaar, R.M., Lopes da Silva, F.H., 2007. The hemodynamic response of the alpha rhythm: an EEG/fMRI study. *NeuroImage* 35, 1142–1151.
- de Munck, J.C., Gonçalves, S.I., Mammoliti, R., Heethaar, R.M., Lopes da Silva, F.H., 2009. Interactions between different EEG frequency bands and their effect on alpha-fMRI correlations. *NeuroImage* 47, 69–76.
- Dittrich, A., 1998. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. *Pharmacopsychiatry* 31 Suppl 2, 80–84.

- Homs, R., Barbanoj, M.J., Riba, J., 2012. Pharmacology of ayahuasca administered in two repeated doses. *Psychopharmacology (Berl.)* 219, 1039–1053.
- Dos Santos, R.G., Valle, M., Bouso, J.C., Nomdedéu, J.F., Rodríguez-Espinosa, J., McIlhenny, E.H., Barker, S.A., Barbanoj, M.J., Riba, J., 2011. Autonomic, neuroendocrine, and immunological effects of ayahuasca: a comparative study with d-amphetamine. *J. Clin. Psychopharmacol.* 31, 717–726.
- Fernández, X, Guimaraes dos Santos, R, Cutchet, M, Fondevila, S, González, D, Alcázar-Córcoles, MA, Riba, J, Bouso, JC, Fábregas, JM, 2014. Assessment of the Psychotherapeutic Effects of Ritual Ayahuasca Use on Drug Dependency: A Pilot Study, in: Labate, BC, Cavnar, C (Eds.), *The Therapeutic Use of Ayahuasca*. Springer-Verlag, Heidelberg, pp. 183–196.
- Fontanilla, D., Johannessen, M., Hajipour, A.R., Cozzi, N.V., Jackson, M.B., Ruoho, A.E., 2009. The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. *Science* 323, 934–937.
- Frood, A., 2015. Ayahuasca psychedelic tested for depression. *Nature* doi:10.1038/nature.2015.17252.
- Gerstl, F., Windischberger, C., Mitterhauser, M., Wadsak, W., Holik, A., Kletter, K., Moser, E., Kasper, S., Lanzenberger, R., 2008. Multimodal imaging of human early visual cortex by combining functional and molecular measurements with fMRI and PET. *NeuroImage* 41, 204–211.
- Goldman, R.I., Stern, J.M., Engel, J., Cohen, M.S., 2002. Simultaneous EEG and fMRI of the alpha rhythm. *Neuroreport* 13, 2487–2492.
- Hayashi, T., Su, T.-P., 2007. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. *Cell* 131, 596–610.

agonists inhibit behavioural and electrophysiological effects of DOI in mice.

*Pharmacol. Biochem. Behav.* 73, 327–332.

Kometer, M., Schmidt, A., Jäncke, L., Vollenweider, F.X., 2013. Activation of

serotonin 2A receptors underlies the psilocybin-induced effects on  $\alpha$  oscillations,

N170 visual-evoked potentials, and visual hallucinations. *J. Neurosci* 33, 10544–

10551.

Lamas, X., Farré, M., Llorente, M., Camí, J., 1994. Spanish version of the 49-item short

form of the Addiction Research Center Inventory (ARCI). *Drug Alcohol*

*Depend.* 35, 203–209.

Laufs, H., Kleinschmidt, A., Beyerle, A., Eger, E., Salek-Haddadi, A., Preibisch, C.,

Krakow, K., 2003. EEG-correlated fMRI of human alpha activity. *NeuroImage*

19, 1463–1476.

Martin, W.R., Sloan, J.W., Sapira, J.D., Jasinski, D.R., 1971. Physiologic, subjective,

and behavioral effects of amphetamine, methamphetamine, ephedrine,

phenmetrazine, and methylphenidate in man. *Clin. Pharmacol. Ther.* 12, 245–

258.

McIlhenny, E.H., Pipkin, K.E., Standish, L.J., Wechkin, H.A., Strassman, R., Barker,

S.A., 2009. Direct analysis of psychoactive tryptamine and harmala alkaloids in

the Amazonian botanical medicine ayahuasca by liquid chromatography-

electrospray ionization-tandem mass spectrometry. *J. Chromatogr. A* 1216,

8960–8968.

McKenna, D., Riba, J., 2015. New World Tryptamine Hallucinogens and the

Neuroscience of Ayahuasca. *Curr. Top. Behav. Neurosci.*

Moosmann, M., Ritter, P., Krastel, I., Brink, A., Thees, S., Blankenburg, F., Taskin, B.,

Obrig, H., Villringer, A., 2003. Correlates of alpha rhythm in functional

ACCEPTED MANUSCRIPT  
magnetic resonance imaging and near infrared spectroscopy. *NeuroImage* 20,  
145–158.

- Moreau, A.W., Amar, M., Le Roux, N., Morel, N., Fossier, P., 2010. Serotonergic fine-tuning of the excitation-inhibition balance in rat visual cortical networks. *Cereb. Cortex N. Y. N* 1991 20, 456–467.
- Muthukumaraswamy, S.D., Carhart-Harris, R.L., Moran, R.J., Brookes, M.J., Williams, T.M., Errtizoe, D., Sessa, B., Papadopoulos, A., Bolstridge, M., Singh, K.D., Feilding, A., Friston, K.J., Nutt, D.J., 2013. Broadband cortical desynchronization underlies the human psychedelic state. *J. Neurosci.* 33, 15171–15183.
- Nichols, T.E., Holmes, A.P., 2002. Nonparametric permutation tests for functional neuroimaging: a primer with examples. *Hum. Brain Mapp.* 15, 1–25.
- Osório, F. de L., Sanches, R.F., Macedo, L.R., dos Santos, R.G., Maia-de-Oliveira, J.P., Wichert-Ana, L., de Araujo, D.B., Riba, J., Crippa, J.A., Hallak, J.E., 2015. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. *Rev. Bras. Psiquiatr. São Paulo Braz.* 1999 37, 13–20.
- Pascual-Marqui, R.D., Michel, C.M., Lehmann, D., 1994. Low resolution electromagnetic tomography: a new method for localizing electrical activity in the brain. *Int. J. Psychophysiol. Off. J. Int. Organ. Psychophysiol.* 18, 49–65.
- Riba, J., 2003. *Human Pharmacology of Ayahuasca*. Autonomous University of Barcelona, Barcelona, Spain.
- Riba, J., Anderer, P., Jané, F., Saletu, B., Barbanoj, M.J., 2004. Effects of the South American psychoactive beverage ayahuasca on regional brain electrical activity in humans: a functional neuroimaging study using low-resolution electromagnetic tomography. *Neuropsychobiology* 50, 89–101.

- ACCEPTED MANUSCRIPT
- Riba, J., Anderer, P., Morte, A., Urbano, G., Jané, F., Saletu, B., Barbanoj, M.J., 2002a. Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers. *Br. J. Clin. Pharmacol.* 53, 613–628.
- Riba, J., McIlhenny, E.H., Bouso, J.C., Barker, S.A., 2015. Metabolism and urinary disposition of N,N-dimethyltryptamine after oral and smoked administration: a comparative study. *Drug Test. Anal.* 7, 401–406.
- Riba, J., Rodríguez-Fornells, A., Barbanoj, M.J., 2002b. Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively. *Psychopharmacology (Berl.)* 165, 18–28.
- Riba, J., Rodríguez-Fornells, A., Strassman, R.J., Barbanoj, M.J., 2001a. Psychometric assessment of the Hallucinogen Rating Scale. *Drug Alcohol Depend.* 62, 215–223.
- Riba, J., Rodríguez-Fornells, A., Urbano, G., Morte, A., Antonijoan, R., Montero, M., Callaway, J.C., Barbanoj, M.J., 2001b. Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers. *Psychopharmacology (Berl.)* 154, 85–95.
- Riba, J., Romero, S., Grasa, E., Mena, E., Carrió, I., Barbanoj, M.J., 2006. Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant. *Psychopharmacology (Berl.)* 186, 93–98.
- Riba, J., Valle, M., Urbano, G., Yritia, M., Morte, A., Barbanoj, M.J., 2003a. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. *J. Pharmacol. Exp. Ther.* 306, 73–83.

- Riba, J., Valle, M., Urbano, G., Yritia, M., Morte, A., Barbanoj, M.J., 2003b. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. *J. Pharmacol. Exp. Ther.* 306, 73–83.
- Romei, V., Brodbeck, V., Michel, C., Amedi, A., Pascual-Leone, A., Thut, G., 2008a. Spontaneous fluctuations in posterior alpha-band EEG activity reflect variability in excitability of human visual areas. *Cereb. Cortex N. Y. N 1991* 18, 2010–2018.
- Romei, V., Gross, J., Thut, G., 2010. On the role of prestimulus alpha rhythms over occipito-parietal areas in visual input regulation: correlation or causation? *J. Neurosci.* 30, 8692–8697.
- Romei, V., Rihs, T., Brodbeck, V., Thut, G., 2008b. Resting electroencephalogram alpha-power over posterior sites indexes baseline visual cortex excitability. *Neuroreport* 19, 203–208.
- Romero, S., Mañanas, M.A., Barbanoj, M.J., 2008. A comparative study of automatic techniques for ocular artifact reduction in spontaneous EEG signals based on clinical target variables: a simulation case. *Comput. Biol. Med.* 38, 348–360.
- Rousseaux, C.G., Greene, S.F., 2015. Sigma receptors [ $\sigma$ Rs]: biology in normal and diseased states. *J. Recept. Signal Transduct. Res.* 1–62.
- Sanches, R.F., de Lima Osório, F., Dos Santos, R.G., Macedo, L.R.H., Maia-de-Oliveira, J.P., Wichert-Ana, L., de Araujo, D.B., Riba, J., S Crippa, J.A., Hallak, J.E.C., 2016. Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study. *J. Clin. Psychopharmacol.* 36, 77–81.
- Savli, M., Bauer, A., Mitterhauser, M., Ding, Y.-S., Hahn, A., Kroll, T., Neumeister, A., Haeusler, D., Ungersboeck, J., Henry, S., Isfahani, S.A., Rattay, F., Wadsak, W.,

system in healthy subjects using multi-tracer PET. *NeuroImage* 63, 447–459.

Schultes, R.E., 1980. *The botany and chemistry of hallucinogens*, Thomas (ed.),  
Springfield, Ill.

Soler, J., Elices, M., Franquesa, A., Barker, S., Friedlander, P., Feilding, A., Pascual,  
J.C., Riba, J., 2015. Exploring the therapeutic potential of Ayahuasca: acute  
intake increases mindfulness-related capacities. *Psychopharmacology (Berl.)*.  
doi:10.1007/s00213-015-4162-0

Strassman, R.J., Qualls, C.R., Berg, L.M., 1996. Differential tolerance to biological and  
subjective effects of four closely spaced doses of N,N-dimethyltryptamine in  
humans. *Biol. Psychiatry* 39, 784–795.

Strassman, R.J., Qualls, C.R., Uhlenhuth, E.H., Kellner, R., 1994. Dose-response study  
of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary  
results of a new rating scale. *Arch. Gen. Psychiatry* 51, 98–108.

Suzuki, O., Katsumata, Y., Oya, M., 1981. Characterization of eight biogenic  
indoleamines as substrates for type A and type B monoamine oxidase. *Biochem.  
Pharmacol.* 30, 1353–1358.

Tsai, S.-Y.A., Pokrass, M.J., Klauer, N.R., De Credico, N.E., Su, T.-P., 2014. Sigma-1  
receptor chaperones in neurodegenerative and psychiatric disorders. *Expert  
Opin. Ther. Targets* 18, 1461–1476.

Tsai, S.-Y., Hayashi, T., Harvey, B.K., Wang, Y., Wu, W.W., Shen, R.-F., Zhang, Y.,  
Becker, K.G., Hoffer, B.J., Su, T.-P., 2009. Sigma-1 receptors regulate  
hippocampal dendritic spine formation via a free radical-sensitive mechanism  
involving Rac1xGTP pathway. *Proc. Natl. Acad. Sci. U. S. A.* 106, 22468–  
22473.



maximization? *Int. J. Drug Policy* 19, 297–303.

Vollenweider, F.X., Vollenweider-Scherpenhuyzen, M.F., Bäbler, A., Vogel, H., Hell,

D., 1998. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. *Neuroreport* 9, 3897–3902.

Accepted manuscript

**Figure 1:** Significance probability maps showing differences between the three administered active treatments and placebo. These maps show changes at the 19 leads placed over the scalp. They depict modifications in absolute power in three different frequency bands and in the deviation of the center-of-gravity frequency (centroid deviation). The four rows from top to bottom show: 1) changes in delta (0.5-3.5 Hz) power; 2) changes in theta (3.5-7.5 Hz) power; 3) changes in alpha (7.5-13 Hz) power; 4) changes in centroid deviation. The vertex view shows the nose at the top, the left ear to the left, the right ear to the right. Electrode positions are indicated by white dots. Warm colors denote increases and cold colors decreases at the significance level indicated by the color bar.

**Figure 2:** Effects of the three administered active treatments vs. placebo on current source density. These maps show the intracerebral current density distribution associated with energy changes recorded at the scalp. The color coding represents statistical significance above a critical value calculated using the non-parametric Holmes permutation test to correct for multiple comparisons. Results are shown for the delta band (0.5-3.5 Hz) in the top rows, the theta band (3.5-7.5 Hz) in the middle rows, and the alpha band (7.5-13 Hz) in the bottom rows. Cold colors denote significant decreases and warm colors significant increases compared to placebo (placebo+placebo) after Holmes correction ( $p < 0.05$ ). The color bars indicate the critical t-value for each frequency band and statistical comparison.

**Figure 3:** Mean scores on the Hallucinogen Rating Scale (HRS), Addiction Research Center Inventory (ARCI) and Altered States of Consciousness (Aussergewöhnliche Psychische Zustände, APZ) subscales for the three active treatments administered and placebo. Error bars denote 1 standard error of mean (n=12). Significant differences from placebo are denoted as \* at p<0.05, \*\* at p<0.01, and \*\*\* at p<0.001. Significant differences between ayahuasca alone and ayahuasca after pretreatment with ketanserin are denoted as † at p<0.05, †† at p<0.01, and ††† at p<0.001. All pair-wise comparisons are shown after Bonferroni correction. Green: placebo, red: ayahuasca, yellow: ketanserin, blue: ketanserin+ayahuasca. The abbreviations indicate: Pla: placebo, Aya: Ayahuasca equivalent to 0.75 mg DMT /Kg body weight, Ket: 40 mg ketanserin, Aya+Ket: combined treatment ayahuasca + ketanserin. ARCI – A: Amphetamine scale; BG: Benzedrine-Group; MBG: Morphine-Benzedrine-Group; PCAG: Pentobarbital-Chlorpromazine-Alcohol-Group; LSD: Lysergic acid diethylamide scale. APZ-OSE: Oceanic boundlessness, AIA: Dread of ego dissolution, VUS: Visionary restructuring.

**Figure 4:** Mean scores on the visual analogue scales (VAS) items for the three active treatments administered and placebo. Error bars denote 1 standard error of mean (n=12). AE: any effect; GE: good effects; BE: bad effects; LK: liking; FE: fear; TI: modifications of time perception; HI: feeling “high”; RE: changes in external reality; CO: loss of contact with external reality; VI: visions. Significant differences from placebo are denoted as \* at p<0.05, \*\* at p<0.01, and \*\*\* at p<0.001. Significant differences between ayahuasca alone and ayahuasca after pretreatment with ketanserin are denoted as † at p<0.05, †† at p<0.01, and ††† at p<0.001. All pair-wise comparisons are shown after Bonferroni correction. Green: placebo, red: ayahuasca, yellow: ketanserin, blue: ketanserin+ayahuasca.

**Figure 5:** Scatter plots showing the relationship between current density changes and the intensity of subjective effects as measured by visual analogue scales (VAS) and expressed in millimeters from 0 to 100. Top panel: decreases in alpha and the VAS “visual effects” ( $r=-0.593$ ,  $p=0.042$ ); Middle panel: decreases in theta and the VAS “contact with external reality” ( $r=-0.591$ ,  $p=0.043$ ); and Bottom panel: decreases in delta and the VAS “contact with external reality” ( $r=-0.724$ ,  $p=0.008$ ).

### **Acknowledgements**

This study was funded by the Beckley Foundation. The authors wish to thank the volunteers for their participation. Marta Valle was supported by FIS through a grant (CP04/00121) from the Spanish Health Ministry in collaboration with Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Barcelona. Data analysis work conducted by SR, JAF and MAM was supported in part by the Spanish Ministry of Economy and Competitiveness (MINECO) under contract DPI2014-59049-R.

### **Conflict of interest**

The authors declare no conflict of interest

### **Contributors**

MV, PF, AF and JR conceived the study

AEM, MR and AR-P conducted the experimental sessions

RMA provided logistical support



SR, JFA, MAM and JR analyzed the neurophysiological data



MV, AEM, MR, AR-P and JR analyzed the subjective effects data


SB analyzed the ayahuasca used in the study

All authors participated in data interpretation, contributed to and have approved the final manuscript

This work was funded by The Beckley Foundation. Amanda Feilding and Pablo Friedlander from the Beckley Foundation actively participated in the design of the study; analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.







**Table 1** Areas showing significant current density differences between active treatments and placebo (placebo+placebo). The number of significant voxels, percentage of significant voxels in a lobe, maximum t value in a lobe and MNI coordinates of the voxel with the maximum t value are reported.

Lobe	Placebo+Ayahuasca				Ketanserina+Placebo				Ketanserina+Ayahuasca			
	N <sup>o</sup> Voxels	% Voxels	x t valu e	MNI x,y,z	N <sup>o</sup> Voxels	% Voxels	x t valu e	MNI x,y,z	N <sup>o</sup> Voxels	% Voxels	x t valu e	MNI x,y,z

#### Alpha

Occipital	761	100	5.86	0,-80,15	-	-	-	-	-	-	-	-
Parietal	691	60	-	-	-	-	-	-	-	-	-	-
Limbic	412	54	-	-	-	-	-	-	-	-	-	-
Temporal	265	23	-	-	-	-	-	-	-	-	-	-

ACCEPTED MANUSCRIPT												
Frontal	144	7	-	-	-	-	-	-	-	-	-	
Sub_lo bar	33	14	-	-	-	-	-	-	-	-	-	
<i>Theta</i>												
Frontal	435	20	4.1	35,50, 25	196	9	3.4	35,10, 60	1090	50	4.0 8	60,0, 10
Limbic Sub_lo bar	46	6	-	-	-	-	-	-	651	86	-	-
Tempor al	8	3	-	-	-	-	-	-	227	99	-	-
Parietal Occipit al	-	-	-	-	31	3	-	-	1154	99	-	-
	-	-	-	-	-	-	-	-	1091	95	-	-
	-	-	-	-	-	-	-	-	761	100	-	-
<i>Delta</i>												
Tempor al	187	16	3.6	40,- 10,-40	-	-	-	-	544	47	4.3 8	25,- 75,10
Limbic Occipit al	92	12	-	-	-	-	-	-	279	37	-	-
Frontal	4	1	-	-	-	-	-	-	761	100	-	-
Parietal Sub- lobar	-	-	-	-	-	-	-	-	3	0.1	-	-
	-	-	-	-	-	-	-	-	303	26	-	-
	-	-	-	-	-	-	-	-	34	14	-	-

**Table 2**

Statistical analyses of subjective effects measures (HRS, ARCI, and APZ) induced after the four administered treatment combinations  $n=12$ . Pairwise comparisons following Bonferroni correction are shown.

HRS	ANOVA df=3,33	Pairwise comparisons after Bonferroni correction <sup>a</sup>					
		Pla+Pla vs. Pla+Aya	Pla+Pla vs. Ket+Pla	Pla+Pla vs. Ket+Aya	Pla+Aya vs. Ket+Pla	Pla+Aya vs. Ket+Aya	Ket+Pla vs. Ket+Aya
		Somaesthesia	F=21, p<0.001	<0.001*	1.000	0.006*	0.003*
Affect	F=31, p<0.001	<0.001*	1.000	0.088	0.001*	0.001*	0.145
Perception	F=19, p<0.001	0.003*	1.000	0.043*	0.003*	0.013*	0.049*
Cognition	F=10, p=0.001	0.012*	1.000	0.194	0.016*	0.251	0.216



ACCEPTED MANUSCRIPT							
Volition	F=8, p=0.001	1.000	1.000	0.014*	1.000	0.001*	0.008*
Intensity	F=24, p<0.001	<0.001*	1.000	0.003*	<0.001*	0.031*	0.095
<b>ARCI</b>							
MBG	F=32, p<0.001	0.001*	1.000	1.000	<0.001*	<0.001*	1.000
PCAG	F=14, p<0.001	1.000	1.000	<0.001*	1.000	<0.001*	0.007*
LSD	F=13, p<0.001	0.002*	1.000	0.009*	0.017*	1.000	0.002*
BG	F=10, p=0.001	1.000	0.623	0.001*	0.413	0.007*	0.028*
A	F=16, p<0.001	0.004*	1.000	0.385	0.003*	0.003*	0.212
<b>APZ</b>							
OSE	F=11,	0.017*	1.000	0.405	0.027*	0.034*	0.535
AIA	F=7,	0.019*	1.000	0.576	0.028*	0.710	0.873
VUS	F=16,	0.003*	1.000	0.049*	0.004*	0.036*	0.063

Pla: placebo, Aya: Ayahuasca equivalent to 0.75 mg/Kg body weight, Ket: 40 mg ketanserin. ARCI – A: Amphetamine scale; BG: Bazedrine-Group; MBG: Morphine-Bazedrine-Group; PCAG: Pentobarbital-Chlorpromazine-Alcohol-Group; LSD: Lysergic acid diethylamide scale. APZ-OSE: Oceanic boundlessness, AIA: Dread of ego dissolution, VUS: Visionary restructuring. <sup>(a)</sup> exact p values. \* statistically significant.

**Table 3**

Statistical analyses of subjective effects measures (Visual Analog Scales or VAS) induced after the four administered treatment combinations  $n=12$ . Pairwise comparisons are shown following Bonferroni correction.

VAS	ANOVA df=3,33	Pairwise comparisons after Bonferroni correction <sup>a</sup>					
		Pla+Pla vs. Pla+Aya	Pla+Pla vs. Ket+Pla	Pla+Pla vs. Ket+Aya	Pla+Aya: Ket+Pla 2:3	Pla+Aya vs. Ket+Pla	Pla+Aya vs. Ket+Aya
		AE	F=48, p<0.001	<0.001*	1.000	<0.001*	<0.001*
GE	F=62, p<0.001	<0.001*	1.000	0.087	<0.001*	<0.001*	0.023*
BE	F=4, p=0.029	0.099	1.000	0.079	1.000	0.257	0.607

ACCEPTED MANUSCRIPT							
LK	F=53, p<0.001	<0.001*	1.000	0.069	<0.001*	0.001*	0.046*
FE	F=4, p=0.059	0.237	1.000	0.239	0.479	1.000	0.988
TI	F=11, p<0.001	0.015*	1.000	0.018*	0.016*	1.000	0.018*
HI	F=54, p<0.001	<0.001*	1.000	0.026*	<0.001*	0.002*	0.016*
RE	F=18, p<0.001	0.001*	0.800	0.269	0.001*	0.004*	0.338
CO	F=6, p=0.011	0.067	1.000	0.788	0.063	0.297	0.733
VI	F=18, -----	0.001*	1.000	0.030*	0.001*	0.388	0.029*

Pla: placebo, Aya: Ayahuasca equivalent to 0.75 mg/Kg body weight, Ket: 40 mg ketanserin. VAS, Visual analogue scales – AE: any effect; GE: good effects; BE: bad effects; LK: liking; FE: fear; TI: time; HI: feeling “high”; RE: changes in external reality; CO: loss of contact with external reality; VI: visions. <sup>(a)</sup> exact p values. \* statistically significant